DDInter1137 DDInter1435
Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.[L8657,L8660,L8663,L8666,L8669] Medroxyprogesterone acetate was granted FDA approval on 18 June 1959.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Medroxyprogesterone acetate {u} (Compound) resembles {v} (Compound) Medrysone
Medroxyprogesterone acetate {u} (Compound) resembles {v} (Compound) Hydrocortamate
Medroxyprogesterone acetate {u} (Compound) treats {v} (Disease) uterine cancer
Medroxyprogesterone acetate {u} (Compound) binds {v} (Gene) CYP3A4
Medroxyprogesterone acetate {u} (Compound) upregulates {v} (Gene) SPAG4
Medroxyprogesterone acetate {u} (Compound) palliates {v} (Disease) breast cancer
Medroxyprogesterone acetate {u} (Compound) is included by {v} (Pharmacologic Class) Progesterone Congeners
Medroxyprogesterone acetate {u} (Compound) downregulates {v} (Gene) USP22
Medroxyprogesterone acetate {u} (Compound) causes {v} (Side Effect) Palpitations
Medroxyprogesterone acetate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delavirdine
Medroxyprogesterone acetate (Compound) resembles Medrysone (Compound)
Medroxyprogesterone acetate (Compound) resembles Hydrocortamate (Compound)
Medroxyprogesterone acetate (Compound) treats uterine cancer (Disease)
Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene)
Medroxyprogesterone acetate (Compound) upregulates SPAG4 (Gene)
Medroxyprogesterone acetate (Compound) palliates breast cancer (Disease)
Medroxyprogesterone acetate (Compound) is included by Progesterone Congeners (Pharmacologic Class)
Medroxyprogesterone acetate (Compound) downregulates USP22 (Gene)
Medroxyprogesterone acetate (Compound) causes Palpitations (Side Effect)
Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken with Delavirdine